Willing to Pay for Antiviral Treatment of Hepatitis B Patients
Willing to Pay for Antiviral Treatment of Hepa¬titis B Patients
Yuan Y, Iloeje U, Li H, Hay J, Yao GB (2008). Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health, 11:S11–22.
Liaw YF, Sung JJ, Chow WC, Farrell G，Lee CZ ,et al. (2004). Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med, 351:1521–31.
Antonucci G, Mazzotta F, Puoti M, Angeletti C, Girardi E, et al. (2012). Factors associated with access to antiviral treatment in a multicentre cross-sectional study of patients with chronic hepatitis B in Italy. J Viral Hepat, 19: 881–9.
Zhuang H (2010). Standard antiviral treatment of hepatitis B. J Med Res, 39:1-2.
Rasell ME (1995).Cost sharing in health insurance--a reexamination. N Engl J Med, 332:1164–8.
|Issue||Vol 45 No 12 (2016)|
|Section||Letter to the Editor|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|